Status:
ENROLLING_BY_INVITATION
A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products
Lead Sponsor:
A2 Biotherapeutics Inc.
Conditions:
Solid Tumor Cancer
Solid Tumor, Unspecified, Adult
Eligibility:
All Genders
18+ years
Brief Summary
This protocol is to ensure consistent long-term follow-up for delayed safety events in participants who received A2 Bio gene therapy (GT) products.
Detailed Description
This is a long-term follow-up study designed to evaluate delayed safety events and long-term efficacy of A2 Bio GT products for participants who received any amount of A2 Bio GT products in a previous...
Eligibility Criteria
Inclusion
- Received any amount of A2 Bio GT product on a previous A2 Bio interventional study
- Able to provide written informed consent for this long-term follow-up study
- Able to comply with study requirements
Exclusion
- 1\. There are no specific exclusion criteria for this study
Key Trial Info
Start Date :
August 31 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2040
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT06885424
Start Date
August 31 2025
End Date
March 31 2040
Last Update
July 15 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905
2
NYU Langone Medical Center
New York, New York, United States, 10016